The study objectives are to assess over the gliclazide MR-SGLT2i combined treatment course in patients with T2DM adding SGLT2i to gliclazide MR-based therapy.

The primary objective is to determine the effectiveness of adding SGLT2i to gliclazide MR-based therapy in patients with T2DM, as measured by HbA1c changes.

Inclusion Criteria:

• Patient diagnosed with T2DM for at least two years prior to index date
• Patient aged ≥18 years at the index date
• Patient naïve to SGLT2i prior to index date
• Patient treated with gliclazide MR at a minimum daily dose of 60 mg at the index date
• Starting treatment with SGLT2i added to gliclazide MR based therapy, during the eligibility period, with a minimum of 60 days of combined gliclazide MR-SGLT2i treatment
• Presence of at least two assessments of HbA1c laboratory test results from the medical records

Exclusion Criteria:

• Diagnosis of diabetes other than T2DM (e.g., type 1, gestational) at index date
• Use of antidiabetic drugs other than those permitted by the inclusion criteria, at index date

Male and female who are treated by Gliclazide MR 60 at index date and who started with SGLT2i added to gliclazide MR with a minimum of 60 days of these combined treatments during the eligibility period